Cellumen, Inc., a discovery toxicology company, entered an agreement with Mitsubishi Tanabe Pharma Corp. (MTPC), to develop panels of biomarkers that identify toxicity early in the drug development process.     “We’re pleased to announce this collaboration with MTPC,” says D. Lansing Taylor, Ph.D., chief executive of Cellumen. “By working together to develop biomarker panels, we hope to identify toxic liabilities much earlier in the drug development process than currently exists in the market...